<abstract xmlns="http://www.w3.org/1999/xhtml">

<bold>Introduction</bold>: Angiogenesis and vasculogenesis contribute to the development of cancer.
The aim of the present study was to determine the levels of vascular endothelial growth factor-A (VEGF-A) and stromal cellderived factor-1α (SDF-1α) and the count of endothelial progenitor cells (EPCs) in patients with essential thrombocythemia (ET).
<bold>Materials and methods</bold>: The study included a group of 62 patients diagnosed with ET and 25 healthy volunteers. Vascular endothelial growth factor-A and SDF-1α levels were determined by enzyme-linked immunosorbent assays (ELISAs). Endothelial progenitor cells were evaluated by flow cytometry.
<bold>Results</bold>: The study showed significantly higher levels of both VEGF-A and SDF-1α in ET patients compared to controls (Me = 65.22 pg/mL vs Me = 25.34 pg/mL; Me = 2351.17 pg/mL vs Me = 1742.50 pg/mL, respectively). However, we could not demonstrate a different count of EPCs in ET patients compared to healthy controls. Furthermore, in 40 ET patients with JAK2 V617F mutation (65%), only VEGF-A levels were significantly higher compared to JAK2 V617F negative patients (Me = 72.00 pg/mL vs Me = 53.38 pg/mL). SDF-1α levels were significantly elevated in patients over 60 years of age (Me = 2635.00 pg/mL vs Me = 2395.02 pg/mL). We found positive correlations between VEGFA and SDF-1α and between VEGF-A and EPCs.
<bold>Conclusions</bold>: Clinical features such as age over 60 years and Janus 2 kinase (JAK2) mutation may increase angiogenesis in patients with essential thrombocythemia. Despite a positive correlation between VEGF-A and EPCs, the present study suggests weak cooperation between proangiogenic factors and vasculogenesis.
</abstract>

Introduction: Angiogenesis and vasculogenesis contribute to the development of cancer.
The aim of the present study was to determine the levels of vascular endothelial growth factor-A (VEGF-A) and stromal cellderived factor-1α (SDF-1α) and the count of endothelial progenitor cells (EPCs) in patients with essential thrombocythemia (ET).
Materials and methods: The study included a group of 62 patients diagnosed with ET and 25 healthy volunteers. Vascular endothelial growth factor-A and SDF-1α levels were determined by enzyme-linked immunosorbent assays (ELISAs). Endothelial progenitor cells were evaluated by flow cytometry.
Results: The study showed significantly higher levels of both VEGF-A and SDF-1α in ET patients compared to controls (Me = 65.22 pg/mL vs Me = 25.34 pg/mL; Me = 2351.17 pg/mL vs Me = 1742.50 pg/mL, respectively). However, we could not demonstrate a different count of EPCs in ET patients compared to healthy controls. Furthermore, in 40 ET patients with JAK2 V617F mutation (65%), only VEGF-A levels were significantly higher compared to JAK2 V617F negative patients (Me = 72.00 pg/mL vs Me = 53.38 pg/mL). SDF-1α levels were significantly elevated in patients over 60 years of age (Me = 2635.00 pg/mL vs Me = 2395.02 pg/mL). We found positive correlations between VEGFA and SDF-1α and between VEGF-A and EPCs.
Conclusions: Clinical features such as age over 60 years and Janus 2 kinase (JAK2) mutation may increase angiogenesis in patients with essential thrombocythemia. Despite a positive correlation between VEGF-A and EPCs, the present study suggests weak cooperation between proangiogenic factors and vasculogenesis.

Vascular endothelial growth factor, stromal growth factor 1α and endothelial progenitor cells in essential thrombocythemia – is there a link between angiogenesis and vasculogenesis?

Nicolaus Copernicus University in Toruń, Ludwik Rydygier Collegium Medicum in Bydgoszcz, Faculty of Pharmacy

Pomeranian Journal of Life Sciences

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Introduction: Angiogenesis and vasculogenesis contribute to the development of cancer.
The aim of the present study was to determine the levels of vascular...

Vascular endothelial growth factor, stromal growth factor 1α and endothelial progenitor cells in essential thrombocythemia – is there a link between angiogenesis and vasculogenesis?

Pubblicato online: 25 apr 2024

Pagine: 64 - 69

DOI: https://doi.org/10.21164/pomjlifesci.968

Parole chiave
essential thrombocythemia, vasculogenesis, endothelial progenitor cells, vascular endothelial growth factor, stromal cell-derived factor-1α

© 2024 Joanna Boinska et al., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Vascular endothelial growth factor, stromal growth factor 1α and endothelial progenitor cells in essential thrombocythemia – is there a link between angiogenesis and vasculogenesis?

Pubblicato online: 25 apr 2024

Pagine: 64 - 69

DOI: https://doi.org/10.21164/pomjlifesci.968

Parole chiaveessential thrombocythemia, vasculogenesis, endothelial progenitor cells, vascular endothelial growth factor, stromal cell-derived factor-1α

© 2024 Joanna Boinska et al., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Parole chiave
essential thrombocythemia, vasculogenesis, endothelial progenitor cells, vascular endothelial growth factor, stromal cell-derived factor-1α